Takeda sues generics makers over heartburn drug; EU wants to tighten up Trobalt use;

@FiercePharma: ICYMI: Bristol-Myers, AstraZeneca win turnabout at NICE for Forxiga. Diabetes med now backed in some regimens. More | Follow @FiercePharma

@EricPFierce: Will Hospira never learn? FDA warning letter says some problems at India plant same as those recently noted at Rocky Mount. Report | Follow @EricPFierce

@CarlyHFierce: Are corruption/lax regulation in Serbia to blame for lack of interest in Galenika? Valeant the only bidder. Article | Follow @CarlyHFierce

> Japan's Takeda sued generics makers Impax Labs ($IPXL), TWi Pharmaceuticals and Sandoz, a Novartis ($NVS) unit, for stepping on its patent for the acid reflux treatment Dexilant. Report

> European drug regulators called for restrictions on use of Trobalt, an epilepsy drug sold by GlaxoSmithKline ($GSK), after some patients reported abnormal coloring of skin, nails and retina. Report

> Teva Pharmaceutical ($TEVA) said the FDA has accepted its application for less-frequent dosing of its multiple sclerosis drug Copaxone; the proposal would allow twice the usual dose to be given three times a week. Report

> Novo Nordisk ($NVO) asked European regulators to approve Ideglira, a combination drug comprising its insulin drug Tresiba and GLP-1 analogue Victoza. Report

> Federal agencies were instructed to cut their 2015 budget requests 5% more than President Obama outlined to them in April. Report

Medical Device News

@FierceMedDev: Smiths eyes $3B-plus medical biz sale. Report | Follow @FierceMedDev

 @DamianFierce: If you're a hospital and can prove Covidien's oximeters beat Masimo's, you may be due $1 million. Story | Follow @DamianFierce

@MichaelGFierce: Roche, Cook help launch public-private Indiana research institute. Article | Follow @MichaelGFierce

> Mercator raises $6.5M for microinfusion tech. Story

> OmniVision's income, revenue jump in billion-dollar year. News

> Smiths mulls $3B-plus medical biz sale. Article

> Qiagen eyes companion diagnostics with cancer deals. More

Biotech News

@FierceBiotech: ICYMI: Top 10 experimental cancer drugs - 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Discounting wins NICE recommendation for Eylea, another score for Regeneron/Bayer. Report | Follow @JohnCFierce

@RyanMFierce: Satori Pharmaceuticals shuts down after failure of Alzheimer's drug. News | Follow @RyanMFierce

 @EmilyMFierce: Japan launches public-private consortium to hunt for new drugs for infectious diseases. Item | Follow @EmilyMFierce

> Lung cancer spotlighted as prime target for new immunotherapies. Article

> FDA snubs Endo's testosterone drug over REMS concerns. News

> Epizyme scores latest biotech IPO victory to advance cancer pipeline. Story

And Finally... Adding weight loss to treatment for psoriasis helped ease symptoms. Report